Department of Clinical Pharmacy and Biopharmaceutics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Department of Pharmacy, Osaka University Hospital, Suita, Osaka, Japan.
Biopharm Drug Dispos. 2020 Jun;41(6):239-247. doi: 10.1002/bdd.2242. Epub 2020 Jun 25.
Cisplatin is used widely for the treatment of multiple solid tumors. Cisplatin-induced nephrotoxicity is caused by renal accumulation of cisplatin via human organic cation transporter 2 (hOCT2). As lansoprazole, a proton pump inhibitor, is known to inhibit hOCT2 activity, lansoprazole might ameliorate cisplatin-induced nephrotoxicity. A previous study showed that concomitant lansoprazole administration ameliorated nephrotoxicity in patients receiving cisplatin. However, the detailed mechanism remains to be clarified. In the present study, the drug-drug interaction between lansoprazole and cisplatin was examined using hOCT2-expressing cultured cells and rat renal slices. Moreover, the effect of lansoprazole on cisplatin-induced nephrotoxicity and the pharmacokinetics of cisplatin in rats was investigated. In the uptake study, lansoprazole potently inhibited the uptake of cisplatin in hOCT2-expressing cultured cells and rat renal slices. The in vivo rat study showed that concomitant lansoprazole significantly ameliorated cisplatin-induced nephrotoxicity and reduced the renal accumulation of platinum up to approximately 60% of cisplatin alone at 72 h after cisplatin intraperitoneal administration. Furthermore, the renal uptake of platinum at 3 min after intravenous cisplatin administration in rats with cisplatin and lansoprazole decreased to 78% of rats with cisplatin alone. In addition, there was no significant difference in the plasma platinum concentration between rats treated with and without lansoprazole at 3 min after cisplatin intravenous administration. These findings suggested that concomitant lansoprazole ameliorated cisplatin-induced nephrotoxicity by inhibiting rOCT2-mediated cisplatin uptake in rats, thus decreasing cisplatin accumulation in the kidney. The present findings provided important information for the establishment of novel protective approaches to minimize cisplatin-induced nephrotoxicity.
顺铂被广泛用于治疗多种实体肿瘤。顺铂诱导的肾毒性是由于顺铂通过人有机阳离子转运体 2(hOCT2)在肾脏中的积累引起的。已知质子泵抑制剂兰索拉唑抑制 hOCT2 的活性,因此兰索拉唑可能减轻顺铂诱导的肾毒性。先前的研究表明,同时给予兰索拉唑可改善接受顺铂治疗的患者的肾毒性。然而,其详细机制仍需阐明。本研究采用表达 hOCT2 的培养细胞和大鼠肾切片研究了兰索拉唑和顺铂之间的药物相互作用。此外,还研究了兰索拉唑对顺铂诱导的肾毒性的作用以及兰索拉唑对大鼠顺铂药代动力学的影响。在摄取研究中,兰索拉唑可强烈抑制 hOCT2 表达的培养细胞和顺铂肾切片中顺铂的摄取。体内大鼠研究表明,同时给予兰索拉唑可显著改善顺铂诱导的肾毒性,并使顺铂在腹腔注射后 72 小时肾脏中的铂蓄积减少约 60%。此外,与单独给予顺铂的大鼠相比,给予顺铂和兰索拉唑的大鼠在静脉注射顺铂后 3 分钟时肾脏对铂的摄取减少至 78%。此外,在静脉注射顺铂后 3 分钟,给予和未给予兰索拉唑的大鼠的血浆铂浓度之间没有显著差异。这些发现表明,兰索拉唑通过抑制大鼠 rOCT2 介导的顺铂摄取,减轻了顺铂诱导的肾毒性,从而减少了顺铂在肾脏中的蓄积。这些发现为建立新的保护方法以最小化顺铂诱导的肾毒性提供了重要信息。